Drug name: Irinotecan + Dofequidar fumarate


Related CSCTT Targets

ABCG2 [ref.1]Q9UNQ0

Irinotecan, CPT11

Cas.no PubChem ID
97682-44-5 60838
Known Target
DNA topoisomerase 1P11387
DNA topoisomerase I, mitochondrialQ969P6
Structure
...
Introduction
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin.

Dofequidar fumarate

Cas.no PubChem ID
158681-49-3 11979781
Known Target
Multidrug resistance protein 1P08183
Structure
...
Introduction
An orally active, quinoline-derivative inhibitor of ABCB1⁄ P-gp. Phase III clinical trials suggested that dofequidar had efficacy in patients who had not received prior therapy.

Reference

  • [1] Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Katayama, R., et al. (2009).Cancer Sci. 100(11):2060-8.
    19673889. [ 19673889 ]

Back to top